|
|
||||||||
1Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois; and 2Department of Vascular Biology and Thrombosis Research, University of Vienna, Vienna, Austria
Submitted 5 October 2006 ; accepted in final form 6 December 2006
We have previously described protective effects of oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) on pulmonary endothelial cell (EC) barrier function and demonstrated the critical role of cyclopentenone-containing modifications of arachidonoyl moiety in OxPAPC protective effects. In this study we used oxidized phosphocholine (OxPAPC), phosphoserine (OxPAPS), and glycerophosphate (OxPAPA) to investigate the role of polar head groups in EC barrier-protective responses to oxidized phospholipids (OxPLs). OxPAPC and OxPAPS induced sustained barrier enhancement in pulmonary EC, whereas OxPAPA caused a transient protective response as judged by measurements of transendothelial electrical resistance (TER). Non-OxPLs showed no effects on TER levels. All three OxPLs caused enhancement of peripheral EC actin cytoskeleton. OxPAPC and OxPAPS completely abolished LPS-induced EC hyperpermeability in vitro, whereas OxPAPA showed only a partial protective effect. In vivo, intravenous injection of OxPAPS or OxPAPC (1.5 mg/kg) markedly attenuated increases in the protein content, cell counts, and myeloperoxidase activities detected in bronchoalveolar lavage fluid upon intratracheal LPS instillation in mice, although OxPAPC showed less potency. All three OxPLs partially attenuated EC barrier dysfunction induced by IL-6 and thrombin. Their protective effects against thrombin-induced EC barrier dysfunction were linked to the attenuation of the thrombin-induced Rho pathway of EC hyperpermeability and stimulation of Rac-mediated mechanisms of EC barrier recovery. These results demonstrate for the first time the essential role of polar OxPL groups in blunting the LPS-induced EC dysfunction in vitro and in vivo and suggest the mechanism of agonist-induced hyperpermeability attenuation by OxPLs via reduction of Rho and stimulation of Rac signaling.
permeability; lung endothelium; thrombin; lipopolysaccharide; interleukin-6; small guanosine triphosphatases; cytoskeleton; adherens junctions; animals; acute lung injury
This article has been cited by other articles:
![]() |
P. Fu, A. A. Birukova, J. Xing, S. Sammani, J. S. Murley, J. G. N. Garcia, D. J. Grdina, and K. G. Birukov Amifostine reduces lung vascular permeability via suppression of inflammatory signalling Eur. Respir. J., March 1, 2009; 33(3): 612 - 624. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Birukova, E. Alekseeva, I. Cokic, C. E. Turner, and K. G. Birukov Cross talk between paxillin and Rac is critical for mediation of barrier-protective effects by oxidized phospholipids Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L593 - L602. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Birukova, I. Malyukova, V. Poroyko, and K. G. Birukov Paxillin-beta-catenin interactions are involved in Rac/Cdc42-mediated endothelial barrier-protective response to oxidized phospholipids Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L199 - L211. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |